Economics of the Antithymocyte Globulins Thymoglobulin and Atgam in the Treatment of Acute Renal Transplant Rejection

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.17, Iss.3, 2000-03, pp. : 287-293

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Rabbit Antithymocyte Globulin (Thymoglobulin®): A Review of its Use in the Prevention and Treatment of Acute Renal Allograft Rejection

By Deeks Emma D. Keating Gillian M.

Drugs, Vol. 69, Iss. 11, 2009-07 ,pp. : 1483-1512

Adis International

Access to resources Recommend Favorite

Everolimus evades acute rejection following renal transplant

Inpharma, Vol. 1, Iss. 1653, 2008-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Daclizumab: A Review of its Use in the Prevention of Acute Rejection in Renal Transplant Recipients

By Wiseman L.R. Faulds D.

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 1029-1042

Adis International

Access to resources Recommend Favorite

`Thymoglobulin' better than `Atgam' from every perspective

Inpharma, Vol. 1, Iss. 1233, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

`Thymoglobulin' better than `Atgam' from every perspective

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 258, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite